research

Anavex Life Sciences Corporation

wait

Seems crazy to me to unjust approvals that are going on while we wait on legitimate results!!!

But why wait 3 years with that when Anavex 50mg dose is likely better! !

So, if one waits months for an answer and then has to resubmit to another journal it can hold things up.

This is a shitshow till data is presented.

loss

but  losses  and  disappointment  with  Missling.

$AVXL Took my $250 loss and Got out guys too much noise not enough action.

but was faked by the move and held them to expiration and had to book a loss of $19,000.

shareholder

The krout has proven to be an a hole toward shareholders.

Missling is a greedy pig, doesnt see the bad he does by delaying intentionally, not only to shareholders,

i am telling for years that we need to fire that shitty guy just here to full his pockets without any consideration for his shareholders.

.this guy doesnt respect his shareholders and he must be sue for that.

$AVXL fire Missling, he has been here 9 years and done nothing to drive shareholder value other than BS hype

$AVXL why does the company not believe they are beholden to their shareholders?

$AVXL Unfortunately the Investorshub AVXL board has deteriorated to the point that it is basically a board consisting of almost entirely FUD with almost more bashers than true shareholders.

Messling is grossly deficient in anticipating the expectations of shareholders and the market.

$AVXL as corporate shareholder, I have sent an email on dec. 21st and a friendly reminder yesterday to IR - no response yet !!

One hand he says he care for shareholder value, on other hand he is purposely not sharing updates.

shareprice

$AVXL missling next time should change a few letters when hiring and SP will improve: from FDA to FBI former employee.

$AVXL Every time Missling speaks, the SP tanks…..amateurish communication, unbelievable.

It&#39;s stupid, it wastes time (and $$$) and it leaves the company vulnerable with a supressed SP.

Based on Rett alone, SP is well under 100$, sorry to bust your ballown,but please try to stay realist and keep a little credibility!

$AVXL The sp is wrong there must be a glitch

$AVXL not that i am happy with the SP overall

$AVXL Until you realize that and admit that the presenter screwed up in rushing the presentation the SP will stay where it’s at

$AVXL wandering when we will cross ANVS SP ;) 
never again!!!!

$AVXL we didnt cross ANVS SP yet, no good haha!

show

Take your money from this shit show and deposit in your bank account.

What an absolute unregulated criminal shit show this market has become.

Missling shows poor judgement and is not suited to be ceo.

SHOWS THE EXTREME WEAKNESS AND  DISTRESS THE STOCK IS UNDER.

but need more time to evaluate and announce a conference call for Monday instead we have a shit show.

I made good profits on Friday and have left profits in stock in support of the research.

Also like the fact that the drug intervenes in tau blocking as that is also a target in AD research.

Research would show there is a significant chance of awesome results here,

Brilliant because the government in Australia recognizes the value of research and grants 43.5% return on each dollar spent.

business-result

Anavex&#39;s A2-73 Blarcamesine&#39;s trial results on 2 previously completed adult phase-3 trials were highly successful.

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer&#39;s is the most valuable and most difficult indication and most desired lately..  and only Anavex really has some great results with a great safety record. .

The  sava  results  trounce  you  guys  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

drug

- Timo grimmer is in the team 
- All endpoints of the clinical trial were reached 
 
I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

we have a drug, even many drugs, good for so many indications,  to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

I&#39;m looking forward to seeing the long term AD data on ANVS and have the feeling it&#39;s going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

trial

$AVXL amazing  avxl  still  in  singke  digits  after  a  supposedly  amazing  “pivotal”  trial  readout  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA  eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

patient

It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Half the patients improved over baseline over 1 year.

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Anavex has over 760 patients that have taken it without any significant issues. .

Lam Research Corp.

rating

shit

Need to short this crap lollllllll!!!!!!!! Brrrrrr!!!

Fuck, AMD has to find someone red to sell off with

Has to bounce a bit before going to shit. No?

Lam Research upgraded by KGI Securities to outperform.

$LRCX (+1.8% pre) Lam Research Posts Strong Earnings.

Shares of Lam Research are down 56% year-to-date and are cheaper than ever.

earnings

$LRCX $EPD $UPS  CRWD CrowdStrike Holdings Options Ahead Of Earnings 
 
📈FREE trade-of-week via(Google Search) ⟶  𝐟𝐫𝐞𝐞𝐚𝐥𝐞𝐫𝐭.𝐩𝐰

so good huh😅..Anyway, cubie dont feel like shorting nice earnings especially wen dia stock has sold off so much in just last month.

$LRCX - earnings and guidance are great…buy the dip…near term 400…imo

$LRCX without the China headwind we would be over 600 now with such stellar earnings

china

Think it will still do well, even w/  up to $2.5 bln revenue hit from U.S. curbs on China exports

buying

$LRCX time to start seriously thinking of buying this.

Forrester Research Inc.

$FORR NEW ARTICLE : Analysts Are Bullish on These Services Stocks: Forrester Research (FORR), PaySign (PAYS) https://www.stck.pro/news/FORR/37328677

Top Stocks matching your search for "shares research"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.